Rasagiline Teva Pharmaceutical

Current Opinion in Investigational Drugs

Volumn 3, Issue 5, 2002, Pages 794-797

  Kupsch, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMPHETAMINE DERIVATIVE; APOPTOSIS INHIBITOR; HALOPERIDOL; LEVODOPA; METIROSINE; MONOAMINE OXIDASE B INHIBITOR; N (2 PROPYNYL) 1 INDANAMINE; PLACEBO; RASAGILINE; SELEGILINE; TV 1012; TV 3219; TVP 101; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ALZHEIMER DISEASE; APOPTOSIS; CATALEPSY; CLINICAL TRIAL; COGNITION; DEGENERATIVE DISEASE; DEPRESSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HEAD INJURY; HUMAN; HYPOKINESIA; INHIBITION KINETICS; MEMORY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; REVIEW; SIDE EFFECT; STROKE; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; ANIMALS; CLINICAL TRIALS; HUMANS; INDANS; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036591271     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. 72058 Monoamine oxidase activity and monoamine metabolism in brains of Parkinsonian patients treated with I-deprenyl. Riederer P, Youdim MBH 1986 46 5 1359-1365
2. 182570 TVP-1012 (Rasagiline mesylate). Teva Pharmaceutical Industries Ltd Company Communication 1995 August 02
3. 195214 N-propagyl-1(R)-aminoindan (TVP-1012), a putative neuroprotective agent, enhances in vitro neuronal survival after glutamate toxicity. Yoles E, Schwartz M, Abstr Soc Neurosci 1995 21 Pt1 Abs 230.18
4. 246792 Pharmacology and neuroprotective properties of rasagiline. Finberg JP, Lamensdorf I, Commissiong JW, Youdim MB J Neural Transm Suppl 1996 48 95-101
5. 270359 Interim report, April-June 1997. Teva Pharmaceutical Industries Ltd 2nd Quarter Report 1997 June
6. 290750 Annual Report 1997 - Teva Pharmaceuticals. Teva Pharmaceuticals Ltd Annual Report 1997 December 31
7. 300018 Effects of N-propargyl-1-(R)-aminoindan (rasagiline) in models of motor and cognition disorders. Speiser Z, Levy R, Cohen S J Neural Transm Suppl 1998 52 287-300
8. 300021 Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. Lamensdorf I, Youdim MB, Finberg JP J Neurochem 1996 67 4 1532-1539
9. 300024 Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPAin hemiparkinsonian rats. Finberg JP, Wang J, Goldstein DS, Kopin IJ, Bankiewicz KS J Neurochem 1995 65 3 1213-1220
10. 300040 1-Methyl-4-cyclohexyl-1,2,3,6-tetrahydropyridine (MCTP): An alicyclic MPTP-like neurotoxin. Youngster SK, Saari WS, Heikkila RE Neurosci Lett 1987 79 1-2 151-156
11. 300046 Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Heikkila RE, Duvoisin RC, Finberg JP, Youdim MB Eur J Pharmacol 1985 116 3 313-317
12. 300050 Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Kalir A, Sabbagh A, Youdim MB Br J Pharmacol 1981 73 1 55-64
13. 344288 Propargylamines protect dopamine cells from apoptosis induced by a Parkinsonism-inducing neurotoxin N-methyl(R) salsolinol. Maruyama W, Youdim MB, Akao Y, Nakagawa Y, Naoi M Abstr Soc Neurosci 1999 25 Pt 2 Abs 540.17
14. 347018 Teva Pharmaceuticals Industriesl Ltd and H Lundbeck A/S form strategic alliance for the codevelopment and European marketing rights of two Parkinson's disease drugs. Teva Pharmaceutical Industries Ltd Press Release 1999 November 09
15. 361999 Teva & Lundbeck announce the successful completion of a phase III trial for a new treatment for Parkinson's patients. Teva Pharmaceutical Industries Ltd Press Release 2000 April 07
16. 387270 Lundbeck pipeline. H Lundbeck A/S Company World Wide Web Site 2000 October 27
17. 388635 Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Carrillo MC, Minami C, Kitani K, Maruyama W, Ohashi K, Yamamoto T, Naoi M, Kanai S, Youdim MB Life Sci 2000 67 5 557-585
18. 388638 Mechanism underlying anti-apoptotic activity of a (-)-deprenyl-related propargylamine, rasagiline. Maruyama W, Yamamoto T, Kitani K, Carrillo MC, Youdim M, Naoi M Mech Ageing Dev 2000 116 2-3 181-191
19. 389417 Teva R&D. Teva Pharmaceutical Industries Ltd Company World Wide Web Site 2000 November 13
20. 396408 Lundbeck pipeline. H Lundbeck A/S Company World Wide Web Site 2001 January 19
21. 406166 Annual Report 2000 - H Lundbeck A/S. H Lundbeck A/S Annual Report 2001 March 01
22. 408145 Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa. Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G Clin Neuropharmacol 2000 23 6 324-330 Rasagiline at varying doses decreased UPDRS scores and was safe and well tolerated.
23. 408149 Neurotoxins induce apoptosis in dopamine neurons: Protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. Maruyama W, Akao Y, Youdim MB, Naoi M J Neural Transm Suppl 2000 60 171-186 Rasagiline prevented caspase activation and the fragmentation of DNA in SH-SY5Y cells.
24. 412170 Product pipeline. H Lundbeck A/S Company World Wide Web Site 2001 June 11
25. 422420 Update on pipeline and Cipralex launch. H Lundbeck A/S Press Release 2001 September 17
26. 428813 Mitochondrial permeability transition pores: A target of apoptosis regulation by rasagiline. Naoi M, Maruyama W, Akao Y, Youdim MB Abstr Soc Neurosci 2001 27 196.11
27. 442321 Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: Comparison of rasagiline (TVP1012) with selegiline. Kupsch A, Sautter J, Gotz ME, Breithaupt W, Schwarz J, Youdim MB, Riederer P, Gerlach M, Oertel WH J Neural Transm 2001 108 8-9 985-1009
28. 442399 Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Maruyama W, Youdim MB, Naoi M Ann NY Acad Sci 2001 939 320-329
29. 442400 The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unelated to MAO inhibition in cell culture and in vivo. Youdim MB, Wadia A, Tatton W, Weinstock M Ann NY Acad Sci 2001 939 450-458
30. 442420 Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Weinstock M, Kirschbaum Slager N, Lazarovici P, Bejar C, Youdim MB, Shoham S Ann NY Acad Sci 2001 939 148-161
31. 442422 Transfection-enforced BCL-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M J Neurochem 2001 78 4 727-735 Rasagiline prevented GAPDH from collecting in the nucleus of cells; this action is believed to be anti-apoptotic.
32. 445657 Morgan Stanley Equity Research Europe: H Lundbeck - Company update: Anxiety - The next step in a significant market. Mann P, Baum A, Moore D Morgan Stanley Dean Witter 2002 March 21
33. 445681 US Pharmaceuticals - Speciality: Teva Pharmaceutical Industries Ltd - Generics leader positioned to outperform. Steinberg DM, Brown RE, Chung EY Deutsche Banc Alex Brown - US 2002 March 12